Plain-English translation of NCT04652115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing , a medication already approved by the FDA for a different condition, to see if it can help people hospitalized with severe COVID-19 pneumonia. The researchers want to understand whether this treatment is safe and whether it works to improve outcomes in patients who need oxygen support or are in the intensive care unit. The study will enroll up to 42 patients divided into two groups based on how sick they are.
Severe COVID-19 can damage the lungs and blood vessels in ways that current treatments don't fully address. This medication may help by protecting blood vessels and reducing harmful inflammation, but it has never been tested in COVID-19 patients before, so researchers need to carefully study its safety and effectiveness.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive as an intravenous infusion every 6 hours while hospitalized. The research team will closely monitor your safety with regular blood tests and vital sign checks, watching especially for any signs of bleeding or blood pressure problems. The study is designed to be flexible—if side effects emerge in early participants, the dose may be adjusted for later participants to find the safest and most effective approach.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Brigham and Women's Hospital
Collaborators
Jazz Pharmaceuticals
Enrollment target
~42 participants
Started
January 2021
Primary completion
December 2026
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in July 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.